Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists develop vaccine for fusobacterium necrophorum
Fusobacterium necrophorum causes infection in livestock and people, but scientists at Kansas State University have found a way to protect animals and humans from the virus.

Bacterium affects both livestock and people

A vaccine that could provide effective, antibiotic-free prevention of Fusobacterium infection has been developed by scientists at Kansas State University.

Fusobacterium necrophroum infection affects both livestock and people. Currently, antibiotics are used to control the bacterium, but researchers say the new vaccine takes an altogether different approach.

"The Food and Drug Administration has prevented the use of many antibiotics in cattle, especially those similar to ones with human applications, so this vaccine is an alternative,” commented Sanjeev K. Narayanan, professor of diagnostic medicine and pathobiology. 

“This way, we don't expose people's food to as many antibiotics, so the vaccine protects both animals and humans."

The vaccine uses a two-pronged approach. It first immunises the animal against leukotoxins, which kill white blood cells and Kupffer cells - the liver’s natural weapons against bacteria.

The team found that Fusobacterium bacterium is able to survive in the liver because it produces leukotoxins. By immunising, if the bacterium enters the liver, there are antibodies built up against it, and the antibodies will neutralise the toxin.

The second element of the vaccine was developed in the lab, where the team identified the protein that allows the bacterium to attach to the walls of the rumen and the liver.

They were then able to identify a major protein in Fusobacterium necrophorum that is responsible for attaching to organs. Antibodies generated in the animal against the protein will prevent bacterial attachment.

"If you can prevent attachment, you can prevent infection," said T.G Nagaraja, a distinguished professor of microbiology. "That's why this patented vaccine uses a two-pronged approach."

The team says the vaccine is currently in testing for cattle, and may eventually be available also for sheep and for people.

Image (C) Kansas State University

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.